Sandoz announced today that its biosimilar pegfilgrastim has been accepted for review by the European Medicines Agency (EMA).
Sandoz announced today that its biosimilar pegfilgrastim has been accepted for review by the European Medicines Agency (EMA).
Sandoz’s product, like its reference, the EU-approved Neulasta, is a long-acting granulocyte-colony stimulating factor. Pegfilgrastim is used in the prophylaxis of chemotherapy-induced febrile neutropenia, and many patients and physicians prefer the drug to short-acting filgrastim because of its less-frequent administration.
"Our goal is to improve patient access to important biologic medicines and the EMA [filing] acceptance of our biosimilar pegfilgrastim is a move towards doing just that," said Mark Levick, MD, PhD, global head of development, biopharmaceuticals. "If approved, we look forward to supporting cancer patients, healthcare professionals, and [payers] with our biosimilar pegfilgrastim."
Sandoz previously withdrew an application for its pegfilgrastim from the EMA; in February, Sandoz notified the Committee for Medicinal Products for Human Use (CHMP) that it would rescind its application for the proposed biosimilar that it had planned to market as Zioxtenzo.
CHMP had noted 2 main concerns about Zioxtenzo, neither of which Sandoz was able to resolve in the timeframe allowed by the regulator: first, study results were unable to demonstrate that concentrations of pegfilgrastim in the blood were the same in patients taking the biosimilar and the reference Neulasta. Second, Sandoz’s proposed manufacturing site had not received a certificate of Good Manufacturing Practice, and an inspection of the facility was still outstanding. “At the time of the withdrawal, the company had not demonstrated that Zioxtenzo is highly similar to Neulasta,” according to the EMA.
Sandoz also experienced disappointment for the drug in the United States; in July 2016, the FDA issued a complete response letter for the proposed biosimilar. Sandoz determined that it would conduct an additional pharmacokinetic study, and reported in early 2017 that it would resubmit its application to the FDA in 2018.
In addition to Sandoz, numerous other biosimilar developers are seeking US and EU regulatory approval for pegfilgrastim molecules; Cinfa Biotech, USV, Mylan—Biocon, Coherus, Gideon Richter, Apotex, and Adello are engaged in developing prospective biosimilars for the top-selling Neulasta.
Overcoming Challenges to Improve Access and Reduce Costs
November 12th 2024Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but realizing this potential will require urgent policy reforms, market competition, and better education for both providers and patients.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: Should mRNA Copies Be Filed as NDAs or Biosimilars?
November 4th 2024The article by Sarfaraz K. Niazi, PhD, argues that the FDA’s classification of future copies of messenger RNA (mRNA) products could be reconsidered, suggesting they might be eligible for new drug applications (NDAs) or a hybrid biosimilar category due to their unique characteristics and increasing prevalence.